May 20

NYBRO, Sweden, May 20, 2011 - The once degraded forests in the Curacautin Valley in Chile have now recovered sufficiently, after hard work over the last decades, to be able to help provide a sustainable living to the people in the area, based on fair trade and responsible forest management principles.

AMSTERDAM, May 20, 2011 - Elsevier, the world-leading publisher of scientific, technical and medical information products and services, in collaboration with the Thai-Journal Citation Index Centre, serving as the database of academic papers published in Thai journals, and the Thailand Research Fund, a government organization in support of national research, announced today the winners of the first-annual TCI-Scopus-TRF Journal Awards.

AMSTERDAM, May 20, 2011 - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.

AMSTERDAM, May 20, 2011 - Agendia (the "Company"), a commercial-stage molecular diagnostic company with operations in the Netherlands and the United States, announces today its intention to raise new funds through an initial public offering ("IPO") on NYSE Euronext in Amsterdam.

HUDDINGE, Sweden, May 20, 2011 - Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.